CPG1 Diabetes Technology: An Endocrine Society Clinical Practice Guideline

Program: Clinical Practice Guidelines
Clinical Session
Friday, April 1, 2016: 9:45 AM-10:45 AM
Hall B2 (BCEC)
Jane E Reusch, MD, Denver Veterans Administration Medical Center, Denver, CO
Anne L Peters, MD, Keck School of Medicine of the University of Southern California, Los Angeles, CA
Task Force Participants:
Andrew J Ahmann, MD, Oregon Health and Science University, Portland, OR and Howard Wolpert, MD, Joslin Diabetes Center/Harvard Med Sch, Boston, MA

ALP: Ad Hoc Consultant, Abbott Laboratories, Ad Hoc Consultant, Astra Zeneca, Ad Hoc Consultant, Eli Lilly & Company, Ad Hoc Consultant, Jansen Pharmaceuticals, Principal Investigator, Jansen Pharmaceuticals, Study Investigator, Lexicon Pharmaceuticals, Inc., Principal Investigator, Medtronic Minimed, Ad Hoc Consultant, Novo Nordisk, Ad Hoc Consultant, Merck & Co., Ad Hoc Consultant, Sanofi, Ad Hoc Consultant, Boehinger-Ingelheim. AJA: Speaker, AACE, Investigator, Dexcom, Investigator, Lexicon Pharmaceuticals, Inc., Investigator, Medtronic Minimed, Investigator, Novo Nordisk, Advisory Group Member, Eli Lilly & Company, Investigator, Sanofi, Advisory Group Member, Sanofi, Consultant, Horizon CME. HW: Investigator, Abbott Laboratories, Investigator, Dexcom, Consultant, Novo Nordisk, Consultant, Insulet, IP, Glooko. Nothing to Disclose: JER Disclosure Not Provided: JER


The Endocrine Society would like to thank the following organizations for their support: AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiasma, Inc.; Corcept Therapeutics Incorporated; Eisai, Inc.; Ethicon Endo-Surgery, Inc.; Genzyme, a Sanofi company, Ipsen Biopharmaceuticals, Inc.; Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Pfizer, Inc.; Shire